Jefferies analyst Maury Raycroft reiterated a Buy rating on Atara Biotherapeutics (NASDAQ: ATRA) yesterday and set a price target of $45. The company’s shares closed yesterday at $36.75.
According to TipRanks.com, Raycroft is a 5-star analyst with an average return of 29.9% and a 58.3% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Intellia Therapeutics, and Reata Pharmaceuticals.
Currently, the analyst consensus on Atara Biotherapeutics is a Strong Buy with an average price target of $57.50, a 56.5% upside from current levels. In a report issued on August 1, Canaccord Genuity also maintained a Buy rating on the stock with a $70 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $54.45 and a one-year low of $12.65. Currently, Atara Biotherapeutics has an average volume of 549.7K.
Based on the recent corporate insider activity of 97 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2018, Matthew K. Fust, a Director at ATRA sold 12,286 shares for a total of $535,301.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
